Tag: lewy body dementia market size

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Growth Projections For The Lewy Body Dementia Market Size During 2025–2029?

The lewy body dementia market size has experienced significant expansion over recent years. This market is projected to grow from $1.12 billion in 2024 to $1.2 billion in 2025, driven by a compound annual growth rate (CAGR) of 7.2%. The historical increase can be attributed to factors such as an expanding aging population, heightened awareness of neurodegenerative diseases, increased healthcare expenditures, refined diagnostic criteria, and regulatory approvals for dementia drugs.

The lewy body dementia market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $1.58 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.1%. This growth during the forecast period is driven by factors such as the rising incidence of dementia, increased investment in research and development, a heightened need for early diagnosis, the broader adoption of telemedicine, and an emphasis on personalized medicine. Key developments anticipated within this timeframe involve the creation of targeted therapies, an increase in clinical trials, improvements in diagnostic methods, progress in technology, and a strong focus on new therapeutic approaches.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp

Which Major Market Drivers Are Shaping The Future Of The Lewy Body Dementia Market?

The lewy body dementia market is projected to grow due to the increasing prevalence of brain-related disorders. These conditions, which involve the brain’s structure and function, typically result in cognitive decline, memory loss, and shifts in behavior. Their rising occurrence is linked to elements like aging, genetic predispositions, and environmental factors. The expanding prevalence of brain disorders heightens the need for improved treatments and earlier detection of lewy body dementia, consequently stimulating research, investment, and innovation, and accelerating progress in LBD diagnosis and therapy. For example, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the world’s population suffers from neurological conditions, a burden anticipated to nearly double by 2050. Ultimately, the growing prevalence of brain-related disorders will fuel the expansion of the lewy body dementia market.

What Are The Emerging Segments Gaining Attention In The Lewy Body Dementia Market?

The lewy body dementiamarket covered in this report is segmented –

1) By Diagnosis: Clinical Diagnosis; Biomarker-Based Diagnosis

2) By Medication: Cholinesterase Inhibitors; Antipsychotics; Antidepressants; Other Medications

3) By End-User: Hospitals; Specialty Clinics; Long-Term Care Facilities; Other End-Users

Subsegments:

1) By Clinical Diagnosis: Neuropsychological Testing; Neurological Examination; Medical History Review; Cognitive Function Assessment

2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers; Imaging Biomarkers (PET, MRI); Genetic Biomarkers; Blood-Based Biomarkers

Which Key Trends Are Expected To Influence The Lewy Body Dementia Market In The Coming Years?

Key companies operating in the lewy body dementia market are concentrating on research investment to create more effective neurodegenerative treatments. Research investment involves dedicating financial resources, time, and effort to scientific and technological studies aimed at uncovering new insights, developing innovative solutions, or enhancing current practices. These endeavors support the exploration of diseases and the creation of new medications, all with the primary objective of improving patient outcomes. For example, in March 2023, the National Institute on Aging, a US-based government agency, awarded $21 million to support drug development research for Lewy Body Dementia (LBD). Researchers at the University of Miami Miller School of Medicine are initiating a Phase 2b study of neflamapimod after encouraging early results.

Who Are The Top Performing Companies In The Lewy Body Dementia Market In Recent Years?

Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer’s Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report

How Does The Lewy Body Dementia Market Perform Across Key Geographic Regions?

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Lewy Body Dementia Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21213&type=smp

Browse Through More Reports Similar to the Global Lewy Body Dementia Market 2025, By The Business Research Company

Lewy Body Dementia Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-treatment-global-market-report

Behavioral And Mental Health Software Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/behavioral-and-mental-health-software-global-market-report

Behavioral Biometrics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/behavioral-biometrics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Lewy Body Dementia Market Through 2034?

There has been a substantial expansion in the market size of Lewy body dementia in recent years. Projections indicate growth from $1.12 billion in 2024 to $1.2 billion in 2025, signifying a compound annual growth rate (CAGR) of 7.2%. Several factors have contributed to the growth in the past, including the increasing aging population, heightened attention to neurodegenerative diseases, rise in healthcare expenditures, enhancements in diagnostic standards, and regulatory authorizations for dementia-related medications.

Anticipated robust expansion is on the horizon for the Lewy Body dementia market, predicted to soar to$1.58 billion by 2029″, boasting a compound annual growth rate (CAGR) of 7.1%. The drivers for this projected upturn during the forecast period can be traced back to a rise in dementia prevalence, increased R&D investments, a surge in early diagnosis demand, wider telemedicine usage, and a lean towards personalized medicine. The forecast period also foresees key trends such as the evolution of tailored therapies, widening of clinical trials, advancements in diagnostic methods, technological progression, and a shift of focus towards innovative therapeutics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp

Which Primay Drivers Are Accelerating Growth in the Lewy Body Dementia Market?

An increase in brain-related impairments is set to fuel progression in the lewy body dementia market. These impairments include a variety of conditions that alter the brain’s structure and function, resulting in cognitive degeneration, memory impairment, and behavioral fluctuations. The rise in such disorders can be attributed to aging, genetic factors, and environmental impacts. Such a surge increases the need for enhanced treatments and early diagnosis for lewy body dementia, triggering research, financial backing, and innovation, hence encouraging rapid progress in LBD diagnosis and treatment. For example, as per the World Federation of Neurology’s report in October 2023, neurological conditions affect over 40% of the global population, a statistic expected to nearly double by 2050, according to the UK-based association of national neurological societies. As such, the escalation in brain-related disorders’ prevalence is anticipated to amplify the growth of the lewy body dementia market.

Which Primary Segments of the Lewy Body Dementia Market Are Driving Growth and Industry Transformations?

The lewy body dementiamarket covered in this report is segmented –

1) By Diagnosis: Clinical Diagnosis; Biomarker-Based Diagnosis

2) By Medication: Cholinesterase Inhibitors; Antipsychotics; Antidepressants; Other Medications

3) By End-User: Hospitals; Specialty Clinics; Long-Term Care Facilities; Other End-Users

Subsegments:

1) By Clinical Diagnosis: Neuropsychological Testing; Neurological Examination; Medical History Review; Cognitive Function Assessment

2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers; Imaging Biomarkers (PET, MRI); Genetic Biomarkers; Blood-Based Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21213&type=smp

Which Regions Are Key Players in the Growth of the #Which Primay Drivers Are Accelerating Growth in the Lewy Body Dementia Market?# Market?

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Lewy Body Dementia Industry Dynamics?

Prominent businesses in the lewy body dementia market are channeling their resources into research investment for the advancement of more potent treatments for neurodegenerative disorders. Research investment embodies the allocation of financial resources, time, and energy to scientific and technological investigations with the aim of discovering innovative insights, developing groundbreaking solutions, or refining existing methods. Such investment facilitates the understanding of diseases and the development of new pharmaceutical treatments, with the ultimate aim of enhancing patient health outcomes. For instance, in March 2023, the National Institute on Aging, a government organization in the US, bestowed $21 million to back drug development research specifically for Lewy Body Dementia (LBD). Research professionals at the University of Miami Miller School of Medicine have begun a Phase 2b study of neflamapimod after receiving promising preliminary results.

View the full report here:

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report

What Parameters Are Used to Define the Lewy Body Dementia Market?

Lewy body dementia (LBD) is a neurodegenerative condition caused by abnormal protein deposits in the brain, impacting cognition, movement, and behavior. This results in a gradual decline in both mental and physical abilities, with symptoms including memory loss, hallucinations, tremors, and motor difficulties. Effective management is essential to address the cognitive and physical challenges associated with the disorder.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21213

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.

What is the Anticipated CAGR of the Lewy Body Dementia Market, and What Factors Will Drive It?

The market for lewy body dementia has experienced substantial growth in the past few years. The market, which is projected to expand from $1.12 billion in 2024 to $1.21 billion in 2025, will do so at a compound annual growth rate (CAGR) of 7.5%. Factors such as the increase in the aging population, heightened knowledge of neurodegenerative diseases, escalated healthcare spending, enhanced diagnostic standards, and the authorization of drugs used to treat dementia are to credit for the growth witnessed during the historic period.

Over the coming years, the market size of Lewy body dementia is set to experience robust growth. It’s projected to reach up to $1.60 billion by 2029, with a 7.2% compound annual growth rate (CAGR). This growth can be linked to the rising incidence of dementia, increasing investment in R&D, a growing preference for early diagnosis, the proliferation of telemedicine, and a dedication to personalized medicine. The forecast period is expected to witness a series of major trends including the evolution of targeted therapies, the escalation of clinical trials, advancements in diagnostic techniques, technological breakthroughs, and a priority on innovative therapeutics.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Lewy Body Dementia Market?

The increasing occurrence of brain-related disorders is anticipated to drive the growth of the lewy body dementia market. Brain-related disorders encompass a variety of conditions that impact the structure and function of the brain, leading to cognitive decline, memory loss, and behavioral changes. Factors such as aging, genetic predisposition, and environmental influences contribute to the growing prevalence of such disorders. As a consequence, there is a heightened demand for improved treatments and early detection of lewy body dementia. This, in turn, fuels research, funding, and innovation, resulting in rapid progress in LBD diagnosis and therapy. For instance, in October 2023, the World Federation of Neurology reported that over 40% of the global population suffers from neurological conditions; a figure expected to nearly double by 2050 – as per the UK-based association of national neurological societies. Hence, the growing occurrence of brain-related disorders will spur the lewy body dementia market’s growth.

Which Segments in the Lewy Body Dementia Offer the Most Growth?

The lewy body dementia market covered in this report is segmented –

1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis

2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications

3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users

Subsegments:

1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment

2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI), Genetic Biomarkers, Blood-Based Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=21213&type=smp

What Are the Fastest-Growing Geographies in the How Are Key Drivers in the Industry Acting as Catalysts for the Growth of the Lewy Body Dementia Market? Market?

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Lewy Body Dementia Industry?

Prominent businesses in the lewy body dementia market are placing a strong emphasis on research investment with the aim to innovate more efficacious treatments for neurodegenerative diseases. This entails the commitment of financial assets, time, and hard work to conduct in-depth scientific and technological research which aims to shed new light on unknown areas, create pioneering solutions, or improve existing methods. Through this, it aids in expanding knowledge about diseases and in creating new medications, with the primary focus being on enhancing patient results. For example, in March 2023, the National Institute on Aging, a governmental agency in the US, granted a substantial sum of $21 million to aid research related to drug development for Lewy Body Dementia (LBD). Fueled by positive preliminary results, researchers at the University of Miami Miller School of Medicine are now beginning a phase 2b study of neflamapimod.

View the full report here:

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report

What Are the Key Elements That Define the Lewy Body Dementia Market?

Lewy body dementia (LBD) is a neurodegenerative condition caused by abnormal protein deposits in the brain, impacting cognition, movement, and behavior. This results in a gradual decline in both mental and physical abilities, with symptoms including memory loss, hallucinations, tremors, and motor difficulties. Effective management is essential to address the cognitive and physical challenges associated with the disorder.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21213

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

How has the lewy body dementia market size evolved in recent years?

The market size for Lewy body dementia has seen significant growth in the recent past. Predictions show that it will expand from $1.12 billion in 2024 to $1.21 billion in 2025, with a compound annual growth rate (CAGR) of 7.5%. This growth throughout the historic period is accredited to factors such as the growth of the elderly population, heightened awareness surrounding neurodegenerative diseases, a surge in healthcare spending, refinement of diagnostic criteria, and authorities approving dementia-related drugs.

What are the predictions for the lewy body dementia market size in the coming years?

Impressive growth is foreseen in the lewy body dementia market over the upcoming years, with its value projected to reach $1.60 billion by 2029, reflecting a compound annual growth rate (CAGR) of 7.2%. This acceleration observed in the forecast period is due to several reasons such as the escalating cases of dementia, increased funding for research and development, a surge in demand for early diagnosis, the growth of telemedicine services, and emphasis on personalized medical care. Considerable trends for the forecast period encompass the advancement of targeted treatments, the broadening of clinical trials, improvements in diagnostic methods, technological enhancements, and focus on new therapeutic approaches.

Get your lewy body dementia market report here!

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report

What key factors are fueling the growth of the lewy body dementia market?

The escalating incidence of brain-related disorders is predicted to fuel the expansion of the lewy body dementia market in the future. These disorders include conditions that disrupt the brain’s structure and function, leading to cognitive decline, loss of memory and changes in behavior. The incidence of these disorders is on the rise due to factors like aging, heredity and environmental influences. This increased incidence is enhancing the demand for improved treatments and swift detection for lewy body dementia, subsequently driving research, funding, and innovative approaches. This, in turn, accelerates advancements in LBD diagnosis and treatment methods. For example, the World Federation of Neurology reported in October 2023 that over 40% of the global population is suffering from neurological conditions, as per the UK-based association of national neurological societies. It is projected that this burden will nearly double by 2050. Hence, the increased incidence of brain-related disorders will be a significant driver for the growth of the lewy body dementia market.

How is the global lewy body dementia market divided into key segments?

The lewy body dementia market covered in this report is segmented –

1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis

2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications

3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users

Subsegments:

1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment

2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI), Genetic Biomarkers, Blood-Based Biomarkers

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp

Who are the key firms paving the way for growth in the lewy body dementia market?

Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer’s Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.

What are the key trends shaping the future of the lewy body dementia market?

Major players in the lewy body dementia market are turning their attention to research investment for the creation of more potent remedies for neurodegenerative conditions. The process of research investment combines financial commitment, labor, and duration towards scientific and technology-based studies to unearth fresh knowledge, create innovative methods, or advance existing techniques. This process aids in investigating diseases and developing new drugs, all aiming to enhance the health results of patients. For instance, in March 2023, a US government agency, the National Institute on Aging, granted $21 million as part of the support for drug evolution research for Lewy Body Dementia (LBD). With the beginning of a Phase 2b study of neflamapimod, researchers at the University of Miami Miller School of Medicine are exhibiting promising initial findings.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21213

What regions are contributing significantly to the growth of the lewy body dementia market?

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Global Pancreatic Cancer Diagnostic Global Market Report 2025

https://thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What Long-Term Growth Rate is Expected for the Lewy Body Dementia Market Between 2025 and 2034?

In recent times, there has been a significant expansion in the market size of Lewy body dementia. The market, which is presently valued at $1.12 billion in 2024, is predicted to increase to $1.21 billion in 2025 with a compound annual growth rate (CAGR) of 7.5%. The growth seen in the previous period can be credited to various factors such as increased population aging, heightened awareness about neurodegenerative diseases, a rise in healthcare spending, enhanced diagnostic parameters and regulatory clearance for dementia medications.

In the coming years, the Lewy body dementia market is projected to experience robust growth, reaching a value of $1.60 billion by 2029 at a compounded annual growth rate (CAGR) of 7.2%. Several factors are expected to drive this growth during the forecast period, including the growing occurrence of dementia, increased investment in research and development, a rise in demand for early diagnosis, broadening adoption of telemedicine, and a focus on individualised medicine. Key trends for the forecast period encompass the evolution of targeted therapies, increasing clinical trials, enhancements in diagnostic methodology, technological progress and concentration on groundbreaking therapeutics.

What Factors Are Propelling the Growth of the Lewy Body Dementia Market from 2025 to 2034?

The escalating occurrence of disorders connected to the brain is anticipated to thrust the development of the lewy body dementia market. These brain-concerned disorders include various conditions that impact the structure and operations of the brain, yielding cognitive deterioration, memory erosion, and behavioral alterations. Triggers such as aging, inherited susceptibility, and environmental effects contribute towards the augmentation of such brain-concerned disorders. The amplifying occurrence of these disorders uplifts the quest for enhanced treatments and early recognition for lewy body dementia, thus promoting research, financial support, and innovation, and culminating in accelerated advancements in diagnosis and therapy for LBD. To illustrate, as per the World Federation of Neurology, in October 2023, the national neurological societies from the UK confirmed that neurological conditions affect more than 40% of the global citizens. It’s predicted that this number will nearly be double by 2050. Thus, the surge in the occurrence of brain-related disorders will stimulate the growth of the lewy body dementia market.

Request Your Free Lewy Body Dementia Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21213&type=smp

What Are the Key Firms That Are Driving Transformation in the Lewy Body Dementia Market?

Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer’s Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.

What Current Trends in the Lewy Body Dementia Market Should Industry Players Pay Attention To?

Key players in the lewy body dementia market are prioritizing investment in research with the objective of creating more effective treatments for neurodegenerative conditions. This investment in research signifies a commitment of financial resources, effort, and time to technological and scientific studies designed to unearth fresh insights, innovate solutions or enhance existing methods. It facilitates the exploration of diseases and the development of new drugs, targeting improved patient outcomes. As an illustration, the National Institute on Aging, a governmental agency in the US, granted $21 million in March 2023 to support research into drug development for Lewy Body Dementia (LBD). Following promising early results, researchers at the University of Miami Miller School of Medicine have commenced a Phase 2b study on neflamapimod.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/lewy-body-dementia-global-market-report

How Are Market Segments in the Lewy Body Dementia Industry Positioned for Long-Term Growth?

The lewy body dementia market covered in this report is segmented –

1) By Diagnosis: Clinical Diagnosis, Biomarker-Based Diagnosis

2) By Medication: Cholinesterase Inhibitors, Antipsychotics, Antidepressants, Other Medications

3) By End-User: Hospitals, Specialty Clinics, Long-Term Care Facilities, Other End-Users

Subsegments:

1) By Clinical Diagnosis: Neuropsychological Testing, Neurological Examination, Medical History Review, Cognitive Function Assessment

2) By Biomarker-Based Diagnosis: Cerebrospinal Fluid (CSF) Biomarkers, Imaging Biomarkers (PET, MRI), Genetic Biomarkers, Blood-Based Biomarkers

What Regions Are Driving Expansion in the Lewy Body Dementia Market?

North America was the largest region in the lewy body dementia market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Parameters Define the Lewy Body Dementia Market’s Scope?

Lewy body dementia (LBD) is a neurodegenerative condition caused by abnormal protein deposits in the brain, impacting cognition, movement, and behavior. This results in a gradual decline in both mental and physical abilities, with symptoms including memory loss, hallucinations, tremors, and motor difficulties. Effective management is essential to address the cognitive and physical challenges associated with the disorder.

Browse Through More Similar Reports By The Business Research Company:

Anemia and Other Blood Disorder Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anemia-and-other-blood-disorder-drugs-global-market-report

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Global Pancreatic Cancer Diagnostic Global Market Report 2025

https://thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: